Join
Alpine Immune Sciences Inc. logo

ALPN

NASDAQ

Alpine Immune Sciences Inc.

SectorHealth CareIndustryBiotechnology: Pharmaceutical PreparationsIPO2015
$64.98+0.02 (+0.03%)
News25/Ratings8

Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for B cell-mediated autoimmune/inflammatory diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the research, development, and commercialization of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.

Latest news

25 items

ALPN FAQ

7 questions
  • What does Alpine Immune Sciences Inc. do?
    Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for B cell-mediated...
  • Where does ALPN stock trade?
    Alpine Immune Sciences Inc. (ALPN) is listed on NASDAQ.
  • What sector and industry is ALPN in?
    Alpine Immune Sciences Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
  • When did Alpine Immune Sciences Inc. go public?
    Alpine Immune Sciences Inc. (ALPN) completed its IPO in 2015.
  • What are analysts saying about ALPN?
    Alpine Immune Sciences Inc. has had 8 recent analyst actions on file. The most recent action was from Guggenheim: Buy on 2024-04-09. Recent price targets range from $1400.00 to $4400.00.
  • What companies are similar to ALPN?
    Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ALPN side-by-side with any of them on Quantisnow.
  • How can I track ALPN on Quantisnow?
    Quantisnow aggregates Alpine Immune Sciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ALPN to receive live email and push alerts on every new disclosure.